Bioo Therapeutics, Texas Tech Research Collaborate on siRNA Delivery to T Cells | GenomeWeb

Bioo Therapeutics, a division of Bioo Scientific, said this month that it has signed a collaborative research agreement with Texas Tech University researcher Premlata Shankar to develop methods to deliver siRNAs into T cells.

Under the deal, Shankar will use Bioo's Targeted Transport Technology, which involves joining a carrier agent to a monoclonal antibody to produce a conjugate that is then loaded with an RNAi molecule such as an siRNA or miRNA mimic, to deliver anti-HIV siRNAs into T cells.

Specific terms of the arrangement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.